4D Molecular Therapeutics reported its full year 2024 financial results on February 28, 2025, detailing operational highlights and upcoming milestones. The company recorded a net loss of $160.9 million for 2024, an increase from a net loss of $100.8 million in 2023, reflecting intensified investment in its clinical pipeline.
Research and development expenses rose to $141.3 million for 2024, compared to $97.1 million in 2023, primarily due to the progression of Phase 2 4D-150 trials in wet AMD and DME, along with increased personnel costs. General and administrative expenses also increased to $46.6 million for 2024 from $36.5 million in the previous year.
As of December 31, 2024, the company's cash, cash equivalents, and marketable securities stood at $505 million, a significant increase from $299 million at the end of 2023. This increase was primarily a result of approximately $316 million in net proceeds from a public offering of common stock and prefunded warrants completed in February 2024. This capital infusion is expected to fund planned operations into 2028, covering the imminent start of Phase 3 studies for 4D-150 in wet AMD, with topline results anticipated in the second half of 2027.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.